{
    "id": 32053,
    "fullName": "NF2 K543N",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NF2 K543N does not lie within any known functional domains of the Nf2 protein (UniProt.org). K543N has been identified in the scientific literature (PMID: 31585938), but has not been biochemically characterized and therefore, its effect on Nf2 protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4771,
        "geneSymbol": "NF2",
        "terms": [
            "NF2",
            "ACN",
            "BANF",
            "SCH"
        ]
    },
    "variant": "K543N",
    "createDate": "01/15/2020",
    "updateDate": "01/15/2020",
    "referenceTranscriptCoordinates": {
        "id": 186523,
        "transcript": "NM_000268",
        "gDna": "chr22:g.29681493G>C",
        "cDna": "c.1629G>C",
        "protein": "p.K543N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19807,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 K543N and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34536,
                "profileName": "EML4 - ALK NF2 K543N NF2 mut"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19805,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Lorbrena (lorlatinib) treatment resulted in multiple new lesions after 15 months of therapy in a patient with lung adenocarcinoma harboring EML4-ALK and an acquired NF2 splice site mutation (NM_000268.3:c.886-1G>A), NF2 K543N was detected in the adrenal biopsy at disease progression (PMID: 31585938).",
            "molecularProfile": {
                "id": 34536,
                "profileName": "EML4 - ALK NF2 K543N NF2 mut"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19808,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) and Lorbrena (lorlatinib) combination treatment inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 K543N and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture, and inhibited tumor growth in patient-derived xenograft models (PMID: 31585938).",
            "molecularProfile": {
                "id": 34536,
                "profileName": "EML4 - ALK NF2 K543N NF2 mut"
            },
            "therapy": {
                "id": 9223,
                "therapyName": "Lorlatinib + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34535,
            "profileName": "NF2 K543N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34536,
            "profileName": "EML4 - ALK NF2 K543N NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 186524,
            "transcript": "NM_181825",
            "gDna": "chr22:g.29681493G>C",
            "cDna": "c.1629G>C",
            "protein": "p.K543N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 186522,
            "transcript": "NM_016418",
            "gDna": "chr22:g.29681493G>C",
            "cDna": "c.1629G>C",
            "protein": "p.K543N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 186523,
            "transcript": "NM_000268",
            "gDna": "chr22:g.29681493G>C",
            "cDna": "c.1629G>C",
            "protein": "p.K543N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 186521,
            "transcript": "NM_181832",
            "gDna": "chr22:g.29681493G>C",
            "cDna": "c.1629G>C",
            "protein": "p.K543N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}